Skip to content
Review Open access

Evaluating [18F]-AlF-FAPI-74 PET/CT for diagnosis of the unfavourable CMS4 colorectal cancer subtype (FoCus study): protocol for a prospective, observational, proof-of-concept clinical study

Oct 2026 · BMJ Open · Vol 16 · 0 citations · 62 references
Medicine

Abstract

Abstract Introduction Consensus molecular subtype 4 (CMS4) colorectal cancer (CRC) is characterised by stromal activation, therapy resistance and poor prognosis. Current CMS4 assessment relies on tissue sampling, which is limited by sampling bias due to inter-lesion and intra-lesion heterogeneity. Fibroblast activation protein (FAP) gene-expression is strongly associated with CMS4 status. [18F]-AlF-FAPI-74 positron emission tomography (PET)/ computed tomography (CT) enables non-invasive, whole-body assessment of FAP expression and may therefore provide an imaging-based biomarker for CMS4 status in CRC. Methods and analysis FoCus is a prospective, observational proof-of-concept clinical study including 45 patients (≥18 years) with resectable metachronous or synchronous colorectal liver metastases. Eligible patients must have at least one liver metastasis of ≥15 mm scheduled for surgical resection. Patients will undergo [18F]-AlF-FAPI-74 PET/CT prior to clinically indicated therapeutic interventions, including surgical resection of primary tumours and/or metastases and, when applicable, prior to systemic therapy. The primary endpoint is CMS4 status, determined by RNA sequencing of resected tumour tissue using multi-region sampling to account for spatial heterogeneity. Diagnostic performance of FAPI-PET (index test) for CMS4 classification (reference standard) will be evaluated using receiver operating characteristic analysis at the tumour-level. Secondary endpoints include FAP expression assessed by immunohistochemistry and ELISA. Ethics and dissemination The study has been approved by the institutional review board NedMec+, the Netherlands (protocol 23-298; Clinical Trials Information System EU CT number: 2023-509183-17-00). All participants will provide written informed consent. Results will be disseminated through peer-reviewed publications and scientific conferences. Trial registration number NCT06191120.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.